<DOC>
	<DOC>NCT00673075</DOC>
	<brief_summary>This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery disease.</brief_summary>
	<brief_title>The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Male or female ambulatory outpatients 18 to 85 of age at screening Coronary artery disease as defined by: status post myocardial infarction (heart attack) greater than 14 days post event with no upper time limit (and followed by stress testing with additional imaging (echocardiographic or nuclear) within the 12 months prior to enrollment) and/or angiographic evidence of one or more major coronary arteries narrowing of greater than 50% and/or a history of percutaneous or surgical coronary revascularization greater than 4 months after that procedure at the time of enrollment. Qualifying blood pressure criteria for study entry and for randomization Willing to adhere to exercise stress (treadmill) tests Unstable angina within 7 days of screening Potential coronary surgical/intervention within the next 6 months Have any form of secondary hypertension Have a history of hypersensitivity to nebivolol, metoprolol, carvedilol, or any beta blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>carvedilol</keyword>
	<keyword>Coreg (TM)</keyword>
	<keyword>hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>Nebivolol</keyword>
	<keyword>BYSTOLIC (TM)</keyword>
</DOC>